Figure 2
![Figure 2. Response rate for avatrombopag and placebo cohorts and median [Q1, Q3] PC over time by treatment group in the randomized study. Response rate (proportion of subjects who achieved PC ≥50 × 109/L and minimum PC increase of 20 × 109/L above baseline) at each time point for avatrombopag and placebo cohorts (A) and median [Q1, Q3] platelet count over time by treatment group (B) in the randomized study (LOCF). For each median (second quartile) PC presented in panel B, error bars denote the first (lower value of bar) and third (upper value of bar) quartiles. LOCF, last observation carried forward.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/123/25/10.1182_blood-2013-07-514398/4/3887f2.jpeg?Expires=1735837842&Signature=IEXNEVBf~~10CmeN-zoK5K8RkEPwnN6HTVTdCsid8-~px7tebVWI2ox1RnbTD~CLutZOm9S~bu-QURqy5Kt-OCbWho0jlviY-1axUz0O8~Jq4ee6vaWlhwRLezu-X4uaL2Ewlydn8D~MyTEqg-eYp8kd9vKrx9ZF7zW~kI9Lg3EMRgIux-EffMy-fp0p~y2gNSwiYBkkwJPh1~lqMqXTZp0g~ksXHVdbmPO2eEw8P48OfBTuYHxQlqJPYo5U1aJznuUEpt~pGHiqCIStieMxa6kduemUsmtlv7obV4yqGMiATjtHjSbHZOvF56AA3bi5ivfmGpDUKRl7XTIHQYt-7Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Response rate for avatrombopag and placebo cohorts and median [Q1, Q3] PC over time by treatment group in the randomized study. Response rate (proportion of subjects who achieved PC ≥50 × 109/L and minimum PC increase of 20 × 109/L above baseline) at each time point for avatrombopag and placebo cohorts (A) and median [Q1, Q3] platelet count over time by treatment group (B) in the randomized study (LOCF). For each median (second quartile) PC presented in panel B, error bars denote the first (lower value of bar) and third (upper value of bar) quartiles. LOCF, last observation carried forward.
